Dong'e Ejiao

Dong'e Ejiao, founded in 1952 and publicly listed on the Shenzhen Stock Exchange in July 1996, is a prominent player in China's Pharmaceutical and Healthcare sectors. The company specializes in the large-scale manufacturing of Ejiao and Ejiao series products, alongside traditional Chinese medicines, healthcare products, and biological medicines. Its operations are anchored by a commitment to traditional remedies and modern pharmaceutical development, serving a critical role in the health and wellness market. The company's ticker symbol is SZSE: 423.

With a workforce ranging from 1,000 to 5,000 employees, Dong'e Ejiao operates as a significant entity within its industry. The company reported revenue of $700.5M, underscoring its substantial market presence and operational capacity. This scale enables extensive research, development, and production of its specialized product lines. Interested parties can learn more about the individuals driving this enterprise by visiting Meet Dong'e Ejiao's team. The company's extensive employee base supports its complex manufacturing processes and broad product portfolio.

Dong'e Ejiao's market reach extends beyond its domestic base in China, with products distributed to international regions including Hong Kong, Macao, Southeast Asia, Europe, and the United States. This global distribution network highlights the company's B2B strategy and its ability to meet diverse international market demands for its unique healthcare and pharmaceutical offerings. The company's established presence in multiple continents signifies its importance in the global traditional medicine and healthcare product supply chain.